#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

The episode features a deep discussion about the transformative potential of genetic medicine, particularly through intravenous delivery into the bloodstream. Tim Perris interviews Jake Becraft, CEO and co-founder of Strand Therapeutics, who explains how his company is pioneering programmable genetic medicines capable of targeting and treating diseases with precision. The conversation highlights how current treatments mostly focus on the liver or superficial tumors, but advancements could make it possible to effectively target deep organ metastases and convert cancers into manageable chronic diseases. The discussion emphasizes the importance of infrastructure, delivery systems, and platform technologies in scaling these innovations to impact large populations, drawing parallels with industries like aerospace and tech giants like Apple.

A significant part of the conversation revolves around the regulatory hurdles that slow the development and deployment of new medicines in the US, compared to countries like China and Australia. Jake advocates for reforms such as removing the FDA from direct oversight of early human trials to accelerate innovation, using examples like Australia’s Clinical Trial Notification (CTN) system. They discuss how current regulatory bottlenecks increase costs and timelines, hindering rapid innovation and wider access. The importance of policy leaders understanding and enabling technological advancements is highlighted, alongside the need for collaborative international efforts to stay competitive.

Tim and Jake explore how effective storytelling can make complex scientific advances more accessible and compelling to policymakers, investors, and the public. They discuss the importance of framing problems with urgency and solutions that resonate emotionally, such as the analogy of Uber’s de-risked delivery infrastructure or Apple’s platform ecosystem. The episode underscores the concept of platform therapeutics—building versatile, scalable technologies akin to SpaceX’s rockets or Apple’s devices—that can be adapted for multiple diseases. The discussion stresses the necessity of clear communication, transparency, and consistent messaging to attract capital, talent, and policy support.

The episode emphasizes the need for bold, long-term vision in biotechnology, similar to Elon Musk’s approach in space exploration or Jeff Bezos’ strategy with Amazon. Jake discusses how venture capital often favors incremental advances due to risk-aversion, but true breakthroughs require patient capital and unwavering commitment. He highlights the role of public narratives, investor transparency, and storytelling in conveying this vision, noting the importance of aligning with visionary funds and sovereign wealth entities willing to support high-risk, high-reward projects. The conversation advocates for adopting entrepreneurial mindsets from successful tech and aerospace industries to revolutionize how medicines are developed and deployed.

The discussion recounts the history of biotech pioneers such as Genentech and the evolution of the industry from small startups to large pharmaceutical conglomerates. The hosts draw parallels with groundbreaking companies like Apple, emphasizing how platform-building—like the iPhone—enabled multi-layered ecosystems and vast market impacts. They compare current biotech efforts to tech giants’ strategies, underlining the importance of creating infrastructure, scalable platforms, and storytelling to sustain innovation over decades. The episode underscores that revolutionary change in biotech will come from building foundational platforms and changing the narrative around what is possible.